Antonio L Perez1, Justin L Grodin1, Yuping Wu2, Adrian F Hernandez3, Javed Butler4, Marco Metra5, G Michael Felker3, Adriaan A Voors6, John J McMurray7, Paul W Armstrong8, Randall C Starling1, Christopher M O'Connor3, W H Wilson Tang1. 1. Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH, USA. 2. Cleveland State University, Department of Mathematics, Cleveland, OH, USA. 3. Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA. 4. Cardiovascular Division, Stony Brook University, Stony Brook, NY, USA. 5. Institute of Cardiology, University of Brescia, Brescia, Italy. 6. University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 7. Department of Cardiology, University of Glasgow, Glasgow, UK. 8. Department of Cardiology, University of Alberta, Edmonton, Canada.
Abstract
AIMS: Endothelin-1 (ET-1) is an endogenous vasoconstrictor implicated in pulmonary and systemic hypertension, as well as ventricular dysfunction, through effects on vascular smooth muscle, the kidneys, and cardiomyocytes. We aimed to determine the association between serial ET-1 levels and acute heart failure patient outcomes. METHODS AND RESULTS: We measured plasma ET-1 at baseline, 48-72 h, and 30 days in a cohort of 872 patients hospitalized with acute heart failure from the ASCEND-HF trial (randomized tonesiritide vs. placebo), and its association with 30-day mortality, 180-day mortality, in-hospital death or worsening heart failure, and 30-day mortality or rehospitalization. Median ET-1 was 7.6 [interquartile range (IQR) 5.9-10] pg/mL at baseline, 6.3 (IQR 4.9-8.1) pg/mL at 48-72 h, and 5.9 (IQR 4.7-7.9) pg/mL at 30 days (P < 0.001). Baseline and 48-72 h ET-1 were found to be independently associated with 180-day mortality in a multivariable analysis [hazard ratio (HR) 1.6, 95% confidence interval (CI) 1.3-2.0, P < 0.001 and HR 1.5, 95% CI 1.2-1.9, P = 0.001, respectively, log-transformed]. ET-1 that was measured at 48-72 h was also independently associated with death or worsening heart failure prior to discharge [odds ratio (OR) 1.6, 95% CI 1.03-2.4, P = 0.03]. These independent associations remained significant after including NT-proBNP in the multivariable analysis. CONCLUSIONS: We observed an independent association between elevated ET-1 and short-term in-hospital clinical outcomes and 180-day mortality in hospitalized patients with acute heart failure ET-1 provided additional prognostic information which was incremental to that yielded by NT-proBNP.
RCT Entities:
AIMS: Endothelin-1 (ET-1) is an endogenous vasoconstrictor implicated in pulmonary and systemic hypertension, as well as ventricular dysfunction, through effects on vascular smooth muscle, the kidneys, and cardiomyocytes. We aimed to determine the association between serial ET-1 levels and acute heart failurepatient outcomes. METHODS AND RESULTS: We measured plasma ET-1 at baseline, 48-72 h, and 30 days in a cohort of 872 patients hospitalized with acute heart failure from the ASCEND-HF trial (randomized to nesiritide vs. placebo), and its association with 30-day mortality, 180-day mortality, in-hospital death or worsening heart failure, and 30-day mortality or rehospitalization. Median ET-1 was 7.6 [interquartile range (IQR) 5.9-10] pg/mL at baseline, 6.3 (IQR 4.9-8.1) pg/mL at 48-72 h, and 5.9 (IQR 4.7-7.9) pg/mL at 30 days (P < 0.001). Baseline and 48-72 h ET-1 were found to be independently associated with 180-day mortality in a multivariable analysis [hazard ratio (HR) 1.6, 95% confidence interval (CI) 1.3-2.0, P < 0.001 and HR 1.5, 95% CI 1.2-1.9, P = 0.001, respectively, log-transformed]. ET-1 that was measured at 48-72 h was also independently associated with death or worsening heart failure prior to discharge [odds ratio (OR) 1.6, 95% CI 1.03-2.4, P = 0.03]. These independent associations remained significant after including NT-proBNP in the multivariable analysis. CONCLUSIONS: We observed an independent association between elevated ET-1 and short-term in-hospital clinical outcomes and 180-day mortality in hospitalized patients with acute heart failureET-1 provided additional prognostic information which was incremental to that yielded by NT-proBNP.
Authors: Ping Li; Insa M Schmidt; Venkata Sabbisetti; Maria Clarissa Tio; Alexander R Opotowsky; Sushrut S Waikar Journal: Clin J Am Soc Nephrol Date: 2020-05-07 Impact factor: 8.237
Authors: Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa Journal: Eur J Heart Fail Date: 2017-05-30 Impact factor: 15.534
Authors: Justyna Maria Sokolska; Mateusz Sokolski; Robert Zymliński; Jan Biegus; Paweł Siwołowski; Sylwia Nawrocka-Millward; Ewa Anita Jankowska; John Todd; Waldemar Banasiak; Piotr Ponikowski Journal: ESC Heart Fail Date: 2018-11-13
Authors: Robert Zymliński; Radosław Sierpiński; Marco Metra; Gad Cotter; Mateusz Sokolski; Paweł Siwołowski; Mateusz Garus; Piotr Gajewski; Joanna Tryba; Maria Samorek; Ewa A Jankowska; Jan Biegus; Piotr Ponikowski Journal: ESC Heart Fail Date: 2020-10-16